CARDIOVASCULAR AND HEART HEALTHNorthwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart health of our patients through expert care, advanced education and scientific breakthroughs. By placing an emphasis on listening to our patients’ needs, Bluhm Cardiovascular Institute has become a destination for those who need highly specialized cardiovascular care — from initial diagnoses to second opinions.
The Northwestern Memorial Hospital Cardiology, Heart and Vascular Surgery Program was ranked in the top 10 in the nation and has been the highest-ranked in Illinois for 17 straight years, per U.S. News & World Report, 2024 – 2025. Northwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart and vascular health of our patients through expert care, advanced education and scientific breakthroughs from initial diagnoses to second opinions. Meet our executive leadership team.
|
Saved His Lungs to Save His HeartHow cardiac surgery, interventional cardiology and pulmonology came together to clear the clots deep in Mike's lungs. Read Mike’s story. |
MAGNITUDE |
REACT-AF |
This phase 3, randomized, placebo-controlled study aims to evaluate the efficacy and safety of NTLA-2001 in participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). NTLA-2001, an investigational CRISPR/Cas9 based genome editing therapy, is intended to edit TTR in hepatocytes so the gene stops making the TTR protein. Eligible participants will be randomized in a 2:1 ratio to receive a single infusion of NTLA-2001 or placebo. All participants will be followed for a minimum of 18 months. At completion of the study, participants that received NTLA-2001 will be asked to enroll in a 15 year long-term follow-up study.
|
The purpose of this multi-center, randomized study is to assess whether it is safe and effective to stop oral anticoagulation medications (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF). Participants are randomized to one of two groups: Standard of Care (SOC) Group or Intervention Group. Participants in the SOC group will remain on their previously prescribed oral anticoagulant. Those randomized to the Intervention group will take the oral anticoagulant for 30 days only if a prolonged episode of AF is detected on an AF-sensing Apple smartwatch. Participation will last up to 60 months and requires one visit to the site at time of enrollment, all other follow-up will be conducted virtually.
|
August 2024 Douglas R. Johnston, MD, chief of Cardiac Surgery at Northwestern Medicine Bluhm Cardiovascular Institute, discusses the reasons behind the 32% increase in cardiac surgeries at Northwestern Memorial Hospital over the past year — and what that growth means for patients.
|
Featuring: Patrick M. McCarthy, MD and Stephen F. Chiu, MD
|
Featuring: Stephen F. Chiu, MD
|
Featuring: Sarah E. Chuzi, MD
|
Featuring: Bradley P. Knight, MD
|
|
Heart Failure and Heart Transplantation Downtown Chicago Northern Suburbs Western Suburbs Greater DeKalb County Northwest Suburbs Southern Suburbs |
|
About Us Terms of Use Privacy Policy How to Vote for U.S. News & World Report Best Hospitals
© 2024 Northwestern Medicine® and Northwestern Memorial HealthCare. Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University |